Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies
Damage to the optic nerve and the death of associated retinal ganglion cells (RGCs) by elevated intraocular pressure (IOP), also known as glaucoma, is responsible for visual impairment and blindness in millions of people worldwide. The ocular hypertension (OHT) and the deleterious mechanical forces it exerts at the back of the eye, at the level of the optic nerve head/optic disc and lamina cribosa, is the only modifiable risk factor associated with glaucoma that can be treated. The elevated IOP occurs due to the inability of accumulated aqueous humor (AQH) to egress from the anterior chamber of the eye due to occlusion of ...
Source: Frontiers in Pharmacology - September 17, 2021 Category: Drugs & Pharmacology Source Type: research
Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy
The distribution of prostaglandin-associated periorbitopathy (PAP) graded using the Shimane University PAP Grading System (SU-PAP) among glaucoma/ocular hypertension subjects using a topical FP or EP2 receptor agonist was reported. A 460 consecutive 460 Japanese subjects (211 men, 249 women; mean age ± standard deviation, 69.9 ± 14.5 years) who had used either a FP agonist (0.005% latanoprost, 0.0015% tafluprost, 0.004% travoprost, 0.03% bimatoprost, or fixed combinations of these) or EP2-agonist (0.002% omidenepag isopropyl) for more than 3 months in at least 1 eye were retrospectively enrolled. Age, sex, pr...
Source: Medicine - August 27, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Erratum to Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. Am J Ophthalmol 2020;220:53-63
In the above mentioned article of the December 2020 issue, edits to the CRediT Authorship Contribution Statement were inadvertently missed during the correction process. The corrected roles should be as follows: (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - August 27, 2021 Category: Opthalmology Tags: Erratum Source Type: research
Lasers, Lights, and Compounds for Hair Loss in Aesthetics
Hair loss is a common complaint that is often stressful for patients and a challenge for practitioners to treat. Fortunately, innovations in the field have contributed to growing evidence for several promising topical, oral, and light and energy-based therapies. We have reviewed the current literature about the efficacy of these treatments, including topical agents (finasteride, latanoprost, spironolactone, caffeine, and metformin), oral minoxidil, nutraceuticals, platelet-rich plasma (PRP), low-level laser therapy (LLLT), fractional lasers, and laser-assisted drug delivery. (Source: Clinics in Dermatology)
Source: Clinics in Dermatology - August 8, 2021 Category: Dermatology Authors: Christina M Ring, Robert Finney, Marc Avram Source Type: research
Clinical Trial: Diurnal IOP Fluctuations in Glaucoma Using Latanoprost and Timolol with Self-Tonometry
CONCLUSIONS
Despite variability in IOP responses to latanoprost and timolol, IOP fluctuation with self-tonometry was more consistent in evaluating target IOP, reflecting its importance in ascertaining true IOP response to topical therapies. These findings may impact clinical decision making based on target IOP criteria in patients on topical therapy. (Source: Optometry and Vision Science)
Source: Optometry and Vision Science - August 1, 2021 Category: Opthalmology Tags: CLINICAL TRIALS Source Type: research
Tube Obstruction of a Nonvalved Glaucoma Drainage Device by a Dislocated Soemmering’s Ring
The authors report a case of tube obstruction of a nonvalved glaucoma drainage device (Aurolab aqueous drainage implant; AADI) with a dislocated Soemmering’s ring (SR) leading to a postoperative intraocular pressure (IOP) spike after an initial IOP reduction. A 24-year-old man with bilateral aphakia, bilateral secondary glaucoma developed corneal decompensation in the left eye. The IOP in the left eye was 22 mm Hg with 3 topical IOP-lowering medications (timolol 0.5%, brimonidine 0.2%, and latanoprost 0.005%). To control the IOP before performing a penetrating keratoplasty, AADI was implanted. A good bleb and an IOP ...
Source: Journal of Glaucoma - August 1, 2021 Category: Opthalmology Tags: Case Reports Source Type: research
Efficacy and tolerance of Latanoprost given as a first intention in the treatment of primitive open angle glaucoma in African melanoderm
CONCLUSION: Latanoprost given as first-line monotherapy in POAG in blacks considerably reduces IOP. The incidence of side effects remains low; it is higher at the start of treatment.PMID:34281763 | DOI:10.1016/j.jfo.2021.01.024 (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - July 20, 2021 Category: Opthalmology Authors: A Napo H Aboubakar M Sidibe C F M Tounkara D Konat é T Nadio A Coulibaly M Togo F Sidibe A Boro F Keita F Sylla L Traore Y Le Mer I Cochereau J P Nordmann Source Type: research
Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study
ConclusionThe 24-h IOP curve of patients in the LCFC group was similar to that of the LTFC group, but on the basis of the pulse rate findings, the effect of LCFC on the cardiovascular system over 24 h was less than that of LTFC. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - July 19, 2021 Category: Opthalmology Source Type: research
Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension
ConclusionTravatan ® and Xalatan® have a similar effect on IOP levels and ocular surface parameters in patients with POAG and OHT. (Source: International Ophthalmology)
Source: International Ophthalmology - July 14, 2021 Category: Opthalmology Source Type: research
Prostanoid receptor agonists for glaucoma treatment
AbstractIntraocular pressure reduction is the only available and evidence-based medical therapy for glaucoma. Currently, the first-line eye drops are prostaglandin analogues including latanoprost, travoprost, bimatoprost, and tafluprost. These drugs stimulate intraocular prostanoid false positive (FP) receptors and reduce intraocular pressure by increasing mainly uveoscleral aqueous outflow. For 2 decades since latanoprost was launched, no drug has been comparable in its efficacy. In 2018, a prostanoid EP2 agonist, omidenepag, was launched in Japan. Current FP agonists and EP2 agonists indicate comparable intraocular press...
Source: Japanese Journal of Ophthalmology - July 6, 2021 Category: Opthalmology Source Type: research
Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
CONCLUSION: The existing studies cannot prove that latanoprost, travoprost, bimatoprost, and tafluprost have different responsiveness in OAG/OHT patients. Switching to bimatoprost or travoprost cannot achieve a significant improvement in responsiveness in LNRs. Bimatoprost has a better IOP-reducing efficacy than latanoprost and travoprost. No serious adverse events occurred during treatment with any medication we studied.PMID:34123413 | PMC:PMC8169256 | DOI:10.1155/2021/5586719 (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - June 14, 2021 Category: Opthalmology Authors: Ziyan Cai Mengdan Cao Ke Liu Xuanchu Duan Source Type: research
